eli lilly competition - Stock Newsroom

Novo Nordisk Wegovy Strategy illustrated with GLP-1 injection pen and obesity pill on clinical desk

Novo Nordisk Wegovy Strategy Boom With HD Dose Push

By Maik Kemper • Apr 7, 2026

Can Novo Nordisk’s aggressive Wegovy strategy really outflank Eli Lilly in the GLP-1 obesity war before new rivals scale up? Maik Kemper Editor in Chief…

Novo Nordisk Wegovy Strategy products Wegovy pen and pill highlighted against dark background

Pharma & Healthcare·Stocks·Europe

Novo Nordisk Wegovy Strategy +2.9% Rally After 70% Slide

By Maik Kemper • Mar 31, 2026

Can the aggressive Novo Nordisk Wegovy Strategy subscription push really reverse a 70% stock slide and close the gap to Eli Lilly? Maik Kemper Editor…

Ozempic pen under dramatic light symbolizing Novo Nordisk FDA warning and GLP-1 safety scrutiny

Pharma & Healthcare·Stocks·Europe

Novo Nordisk FDA warning: Safety shock and WHO funding pivot

By Maik Kemper • Mar 11, 2026

Can the Novo Nordisk FDA warning derail the GLP-1 boom just as a new WHO partnership reshapes the company’s global image? How serious is the…